RecruitingNCT06301438
Dalpiciclib in HR+/HER2- ABC
Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
Sponsor
RenJi Hospital
Enrollment
103 participants
Start Date
May 3, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Histologically confirmed advanced breast cancer
- Hormone receptor-positive and human epidermal growth factor receptor 2-negative
- ECOG 0-1
Exclusion Criteria2
- Pregnant or breastfeeding
- History of immunodeficiency
Interventions
DRUGdalpiciclib
dalpiciclib oral day 1-21, every 28 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06301438
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT0699702921 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations